Jim Simons’s Ensysce Biosciences ENSC Stock Holding History

Jim Simons’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,574	Closed	-$36.9K	–	3377
2025 Q3	$36.9K	Buy	+15,574	New	+$33.5K	﹤0.01%	3379
2024 Q4	–	Sell	-1,493	Closed	-$5.38K	–	3659
2024 Q3	$5.38K	Buy	+1,493	New	+$9.06K	﹤0.01%	3476
2024 Q2	–	Sell	-704	Closed	-$8K	–	3604
2024 Q1	$8K	Sell	704 -26	-4%	-$413	﹤0.01%	3634
2023 Q4	$12K	Buy	+730	New	+$11.8K	﹤0.01%	3625
2022 Q3	–	Sell	-99	Closed	-$309K	–	4101
2022 Q2	$309K	Buy	99 +19	+24%	+$53.2K	﹤0.01%	3440
2022 Q1	$328K	Buy	+80	New	+$529K	﹤0.01%	3432

Other funds holding ENSC

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPI

Financial Plan Inc Bellingham, Washington $933M AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

Jim Simons's ENSC Position: Q4 2025 in Review

Jim Simons sold out of Ensysce Biosciences (ENSC) in Q4 2025, closing a stake of 15,574 shares — an estimated $36.9K sold.

Jim Simons first reported a position in ENSC in Q1 2022 and held it in 6 quarters. The position peaked at $328K in Q1 2022. 17 funds tracked by Wall St. Rank hold ENSC as of Q4 2025.

Jim Simons reported no remaining Ensysce Biosciences position as of Q4 2025 after selling out during the quarter.
Jim Simons sold 15,574 Ensysce Biosciences shares in Q4 2025, an estimated $36.9K.
Jim Simons first reported a position in Ensysce Biosciences in Q1 2022 and held it in 6 quarters.
Jim Simons's Ensysce Biosciences position peaked at $328K in Q1 2022.
17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.